Study in Annals of the Rheumatic Diseases bears out efficacy of Cosamin DS
EDGEWOOD, Md. — Nutramax Labs announced Thursday the publication of results from an international clinical study that demonstrates the effectiveness of glucosamine hydrochloride and chondroitin sulfate — the same active ingredients found in the joint health dietary supplement Cosamin DS — in the management of joint health and wellness. The results of the MOVES (Multicentre Osteoarthritis InterVEntion trial with Sysadoa) study are published in the online edition of the peer-reviewed journal, Annals of the Rheumatic Diseases.
“The MOVES trial is truly an important study that provides additional evidence to support the use of glucosamine hydrochloride and chondroitin sulfate, at a daily dose of 1,500 and 1,200 milligrams, respectively, in managing joint health in a wide variety of patient populations,” stated Nicholas DiNubile, clinical associate in the Department of Orthopedic Surgery at the Hospital of the University of Pennsylvania. “This new data is especially encouraging for patients, and it reinforces my ongoing approach to long-term joint health management in my practice, particularly for people who are experiencing a significant increase in the incidence of deteriorating joint health yet wish to remain physically active.”
Cosamin DS is the most researched glucosamine/chondroitin joint health supplement, Nutramax stated. Cosamin DS uses FCHG49 glucosamine and TRH122 chondroitin sulfate, providing a unique combination of ingredients not found in other glucosamine/chondroitin combination dietary supplements. “I tell my patients, not all supplements are created equal – brand matters. It’s important to recommend supplements supported by extensive research like Cosamin,” DiNubile said.
“We were the first company to develop this combination worldwide and publish clinical studies showing its benefits for joint health. We have been conducting both human and veterinary research for over 20 years, so it’s gratifying to see studies of this magnitude that confirm our previous findings. The MOVES study further underscores the value of Cosamin DS as a safe and effective option to support joint health,” said Robert Henderson, chairman Nutramax.
MOVES is a multicenter, randomized, parallel-group, double-blind, controlled clinical trial that enrolled 606 patients at 42 centers in France, Germany, Poland and Spain. The study was sponsored by Bioibérica, suppliers of the chondroitin sulfate used in Cosamin DS. The study was developed as an extension of the GAIT (Glucosamine/Chondroitin Arthritis Intervention Trial) study, which showed that the combination of glucosamine hydrochloride (1,500 mg/day) and chondroitin sulfate (1,200 mg/day) was effective in a moderate to severe subgroup of patients.